TLSA Completes Enrollment in Phase 2a Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis, 48 Patients Enrolled
Tiziana Life Sciences Ltd. Common Shares · Now $1.41
+1.4% in 1d after detection
Post-detection moves
1h
—
1d
+1.4%
3d
+0.7%
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS